REX:NYE-REX American Resources Corporation (USD)

COMMON STOCK | Chemicals |

Last Closing

USD 46.1

Change

+0.55 (+1.21)%

Market Cap

N/A

Volume

0.10M

Analyst Target

USD 95.00
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-04 )

Largest Industry Peers for Chemicals

Symbol Name Price(Change) Market Cap
HUN Huntsman Corporation

+0.50 (+2.11%)

USD 4.25B
BAK Braskem SA Class A

+0.10 (+1.37%)

USD 2.98B
TROX Tronox Holdings PLC

+0.11 (+0.78%)

USD 2.30B
VHI Valhi Inc

+2.37 (+7.34%)

USD 0.94B
ASIX AdvanSix Inc

+0.81 (+2.60%)

USD 0.83B
WLKP Westlake Chemical Partners LP

N/A

USD 0.79B
RYAM Rayonier Advanced Materials

+0.19 (+2.21%)

USD 0.56B
DOW Dow Inc

+0.84 (+1.54%)

N/A
CE Celanese Corporation

+2.77 (+2.07%)

N/A
LXU Lsb Industries Inc

+0.15 (+1.81%)

N/A

ETFs Containing REX

PUW 0.00 % 0.70 %

N/A

N/A
SIXS 6 Meridian Small Cap Equi.. 0.00 % 0.00 %

+0.69 (+1.43%)

USD 0.09B

Market Performance

  Market Performance vs. Industry/Classification (Chemicals) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -2.54% 45% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.54% 36% F 18% F
Trailing 12 Months  
Capital Gain 21.41% 73% C 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 21.41% 73% C 48% F
Trailing 5 Years  
Capital Gain 78.68% 82% B 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 78.68% 82% B 76% C+
Average Annual (5 Year Horizon)  
Capital Gain 20.18% N/A N/A 83% B
Dividend Return 20.18% N/A N/A 81% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 28.67% N/A N/A 36% F
Risk Adjusted Return 70.37% N/A N/A 84% B
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:

There is nothing we particularly dislike